hydroxychloroquine has been researched along with Amaurosis in 10 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening." | 4.12 | Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022) |
| " Differential diagnoses include Leber's congenital amaurosis, central gyrate atrophy, central areolar choroidal sclerosis, progressive cone-rod dystrophy, syphilitic retinopathy, retinal toxicity from phenothiazine use, and chloroquine/hydroxychloroquine retinopathy." | 3.70 | Retinitis pigmentosa inversa. ( Anderson, SF; Ferrucci, S; Townsend, JC, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delavar, A | 3 |
| Baxter, SL | 3 |
| Lee, HJ | 1 |
| Kim, SJ | 1 |
| Ojaimi, E | 1 |
| Guymer, RH | 1 |
| Wong, TY | 1 |
| Harper, CA | 1 |
| Hodson, TJ | 1 |
| Rivett, K | 1 |
| Ferrucci, S | 1 |
| Anderson, SF | 1 |
| Townsend, JC | 1 |
| Frohman, LP | 1 |
| Frieman, BJ | 1 |
| Wolansky, L | 1 |
| Rynes, RI | 1 |
| Krohel, G | 1 |
| Falbo, A | 1 |
| Reinecke, RD | 1 |
| Wolfe, B | 1 |
| Bartholomew, LE | 1 |
| Reich, H | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
2 reviews available for hydroxychloroquine and Amaurosis
| Article | Year |
|---|---|
[Acrodermatitis enteropathica. Clinical picture, life-saving treatment, therapy-induced blindness].
Topics: Acrodermatitis; Blindness; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Infant; Iodoquinol | 1973 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
8 other studies available for hydroxychloroquine and Amaurosis
| Article | Year |
|---|---|
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Sudden visual loss in a patient with systemic lupus erythematosus caused by a combination of the disease itself and drug toxicity.
Topics: Blindness; Cataract Extraction; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus E | 2020 |
Hydroxychloroquine retinopathy: screening needed to prevent blindness.
Topics: Adult; Antirheumatic Agents; Blindness; Female; Humans; Hydroxychloroquine; Retinal Diseases | 2010 |
Hydroxychloroquine retinopathy: screening needed to prevent blindness.
Topics: Antirheumatic Agents; Blindness; Humans; Hydroxychloroquine; Practice Guidelines as Topic; Retinal D | 2011 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Blindness; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; S | 2004 |
Retinitis pigmentosa inversa.
Topics: Adult; Atrophy; Blindness; Chloroquine; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxyc | 1998 |
Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus.
Topics: Blindness; Color Perception; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lupus Erythematosu | 2001 |
Ophthalmologic safety of long-term hydroxychloroquine treatment.
Topics: Accommodation, Ocular; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blindness; Cornea; Female; Hu | 1979 |